Bio Green Med Solution, Inc. filed a Form 8-K on November 20, 2026, reporting the results of a special meeting of shareholders held on November 19, 2026, at which five proposals related to a business combination with Future NRG Sdn Bhd. were each approved by vote.

Key Highlights

  • Quorum reached: 4,935,383 shares were present or represented by proxy, constituting approximately 74.52% of total votes entitled to be cast.
  • Business combination share issuance approved: Proposal 1, covering the issuance of common stock to selling shareholders under the Business Combination Agreement dated June 4, 2026, received 4,178,146 votes for (63.1%) and 66,327 against (1.0%).
  • Nasdaq 20% rule compliance approved: Proposal 2, authorizing issuance of more than 20% of outstanding shares under Nasdaq Listing Rules 5635(a) and 5635(b), received 4,177,953 votes for (63.1%).
  • Authorized shares increase approved: Proposal 3 to amend the Amended and Restated Certificate of Incorporation to increase authorized common stock to 3,000,000,000 shares received 4,844,487 votes for (73.1%).
  • Reverse stock split approved: Proposal 4 authorizing a reverse stock split at a ratio between 1:4 and 1:16, to be determined by the Board of Directors, received 4,894,944 votes for (73.9%).
  • Future financing approved: Proposal 5, permitting the issuance and sale of shares, warrants, and other securities during the 24-month period following the transaction, received 4,177,871 votes for (63.1%).

Special Meeting Voting Results for Bio Green Med Solution's Planned Transaction with Future NRG

According to the filing, as of October 5, 2026, the record date, there were 6,622,794 shares of common stock issued, outstanding, and entitled to vote. The special meeting was conducted as a virtual meeting via live audio webcast, and the Company reported that a quorum was present for the transaction of business. The five proposals voted upon were described in greater detail in a definitive proxy statement filed with the SEC on October 9, 2026.

The filing discloses that Proposal 1 approved the issuance of common stock of BGMS to selling shareholders pursuant to the Business Combination Agreement between BGMS, Future NRG Sdn Bhd., and the selling shareholders, dated June 4, 2026. Proposal 2 addressed compliance with Nasdaq Listing Rule 5635(a) regarding issuances exceeding 20% of outstanding shares and Nasdaq Listing Rule 5635(b) regarding a change of control of BGMS. Both proposals each received 690,759 broker non-votes, representing 10.4% of total votes.

Proposals 3 and 4, which address the amendment to the Amended and Restated Certificate of Incorporation to increase authorized shares to 3,000,000,000 and to effect a reverse stock split, recorded no broker non-votes. Proposal 5, the future financing proposal, permits BGMS to issue shares, warrants, and other linked securities in one or more financing transactions during the 24-month period following the transaction, in compliance with Delaware law, SEC rules, and Nasdaq requirements. The Form 8-K was signed by Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director, on November 20, 2026.

What Was Disclosed

Bio Green Med Solution, Inc. (NASDAQ:BGMS) reported the final voting results from its November 19, 2026 special shareholder meeting, at which all five proposals connected to its planned business combination with Future NRG Sdn Bhd. were approved by stockholders.